Current Approaches to the Development of a Vaccine Against Filarial Nematodes

Immunity to Parasitic Infection

Volumn , Issue , 2012, Pages 459-470

  Lustigman, Sara ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

Anti filarial nematode vaccines; Anti O. volvulus and anti LF vaccines; Human lymphatic filariae, protective immune responses; Jirds in vaccine studies, for lymphatic filariasis; New vaccine candidates; Protective immunity, natural in some; Vaccination against Onchocerca sp.; Vaccines against filarial nematodes; Vaccines against Onchocerca volvulus

Indexed keywords

EID: 84886536239     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118393321.ch28     Document Type: Chapter

References (77)

1. Abraham, D et al. (2002). Immunity to Onchocerca spp. in animal hosts. Trends in Parasitology 18(4), 164-171.
2. Basanez, MG et al. (2008). Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. The Lancet Infectious Diseases 8(5), 310-322.
3. Bergquist, R & Lustigman, S (2010). Control of important helminthic infections: vaccine development as part of the solution. Advances In Parasitology 73, 297-326.
4. Cook, JA et al. (2001). Towards a vaccine for onchocerciasis. Trends in Parasitology 17 (12), 555-558.
5. Dadzie, Y et al. (2003). Final report of the Conference on the eradicability of Onchocerciasis. Filaria Journal 2 (1), 2.
6. Hoerauf, A & Brattig, N (2002). Resistance and susceptibility in human onchocerciasis-beyond Th1 vs. Th2. Trends in Parasitology 18(1), 25-31.
7. Hoerauf, A & Steel, C (2004). Towards a strategic plan for research to support the global program to eliminate lymphatic filariasis-3.2 Protective immunity-vaccines. American Journal of Tropical Medicine and Hygiene 71(S5), 34-36.
8. Lustigman, S et al. (2002). Towards a recombinant antigen vaccine against Onchocerca volvulus. Trends in Parasitology 18(3), 135-141.
9. Nutman, TB (2002). Future directions for vaccine-related onchocerciasis research. Trends in Parasitology 18(6), 237-239.
10. Richards, FO, Jr. et al. (2001). Control of onchocerciasis today: status and challenges. Trends in Parasitology 17(12), 558-563.
11. Tisch, DJ et al. (2005). Mass chemotherapy options to control lymphatic filariasis: a systematic review. The Lancet Infectious Diseases 5(8), 514-523.
12. Williams, S et al. (2002). The River Blindness Genome Project. Trends in Parasitology 18(2), 86-90.
13. Day, KP et al. (1991). Age-specific acquisition of immunity to infective larvae in a bancroftian filariasis endemic area of Papua New Guinea. Parasite Immunology 13(3), 277-290.
14. Kazura, JW (2000). Resistance to infection with lyphoatic dwelling filarial parasites. Imperial College Press, London.
15. Kurniawan-Atmadja, A et al. (1998). Antibody responses to filarial infective larvae are not dominated by the IgG4 isotype. Parasite Immunology 20(1), 9-17.
16. Rajakumar, S et al. (2006). Concomitant immunity in a rodent model of filariasis: the infection of Meriones unguiculatus with Acanthocheilonema viteae. Journal of Parasitology 92(1), 41-45.
17. Tchakoute, VL et al. (2006). In a bovine model of onchocerciasis, protective immunity exists naturally, is absent in drug-cured hosts, and is induced by vaccination. Proceedings of The National Academy Of Sciences Of The United States Of America 103(15), 5971-5976.
18. Trees, AJ et al. (2000). Onchocerca ochengi infections in cattle as a model for human onchocerciasis: recent developments. Parasitology 120(Suppl.) S133-142.
19. Turaga, PS et al. (2000). Immunity to onchocerciasis: cells from putatively immune individuals produce enhanced levels of interleukin-5, gamma interferon, and granulocyte-macrophage colony-stimulating factor in response to Onchocerca volvulus larval and male worm antigens. Infection and Immunity 68(4), 1905- 1911.
20. Sartono, E et al. (1997). Depression of antigen-specific interleukin-5 and interferon- responses in human lymphatic filariasis as a function of clinical status and age. Journal of Infectious Diseases 175(5), 1276-1280.
21. Abraham, D et al. (2001). Development of a recombinant antigen vaccine against infection with the filarial worm Onchocerca volvulus. Infection and Immunity 69(1), 262-270.
22. Cho-Ngwa, F et al. (2010). The Onchocerca volvulus cysteine proteinase inhibitor, O. volvulus-CPI-2, is a target of protective antibody response that increases with age. PLoS Neglected Tropical Diseases 4(8): e800.
23. Erttmann, KD et al. (2005). Cloning, characterization and DNA immunization of an Onchocerca volvulus glyceraldehyde-3-phosphate dehydrogenase (O. volvulus-GAPDH). Biochimica Et Biophysica Acta 1741(1-2), 85-94.
24. Jenkins, RE et al. (1996). Characterization of a secreted antigen of Onchocerca volvulus with host-protective potential. Parasite Immunology 18(1), 29-42.
25. Johnson, EH et al. (1998). Immune responses to third stage larvae of Onchocerca volvulus in interferon- and interleukin-4 knockout mice. Parasite Immunology 20(7), 319-324.
26. Lange, AM et al. (1993). Induction of protective immunity against larval Onchocerca volvulus in a mouse model. American Journal of Tropical Medicine and Hygiene 49(6), 783-788.
27. Lustigman, S et al. (2003). CD4+-dependent immunity to Onchocerca volvulus third-stage larvae in humans and the mouse vaccination model: common ground and distinctions. International Journal for Parasitology 33(11), 1161-1171.
28. Lustigman, S & Abraham, D (2008). Onchocerciasis. Chapter 67, p1379-1400. In: Barrett, ADT & Stanberry, LR (Eds.) Vaccines for biodenfense and Emerging and Neglected Diseases. Academic press, Elsevier Sciences and Technology.
29. Makepeace, BL et al. (2009). Immunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposure. PLoS Neglected Tropical Diseases 3(11): e544.
30. Taylor, MJ et al. (1994). Protective immunity against Onchocerca volvulus and O. lienalis infective larvae in mice. Tropical Medicine and Parasitology 45(1), 17-23.
31. Taylor, MJ et al. (1995). Onchocerca volvulus larval antigen, O. volvulusB20, induces partial protection in a rodent model of onchocerciasis. Infection and Immunity 63(11), 4417-4422.
32. Adam, R et al. (1996). Identification of chitinase as the immunodominant filarial antigen recognized by sera of vaccinated rodents. Journal of Biological Chemistry 271(3), 1441-1447.
33. Anand, S et al. (2006). Comparison of immuno prophylactic efficacy of Bm rALT2 or Bm rVAH or rALT+rVAH by Single and multiple antigen vaccination mode. American Society of Tropical Medicine and Hygiene 75(5), 295.
34. Chusattayanond, W & Denham, DA (1986). Attempted vaccination of jirds (Meriones unguiculatus) against Brugia pahangi with radiation attenuated infective larvae. Journal of Helminthology 60(2), 149-155.
35. Dabir, P et al. (2006). Immunoprophylactic evaluation of a 37 kDa Brugia malayi recombinant antigen in lymphatic filariasis. Clinical Microbiology and Infection 12(4), 361-368.
36. Gregory, WF et al. (2000). The abundant larval transcript-1 and -2 genes of Brugia malayi encode stage-specific candidate vaccine antigens for filariasis. Infection and Immunity 68(7), 4174-4179.
37. Krithika, KN et al. (2005). Identification of 38kDa Brugia malayi microfilarial protease as a vaccine candidate for lymphatic filariasis. Indian Journal of Experimental Biology 43(9), 759-768.
38. Petit, TA et al. (1993). Brugia pahangi: effects of protective resistance on lymphatic lesions and granulomatous inflammation in infected jirds (Meriones unguiculatus). Experimental Parasitology 77(4), 395-404.
39. Pfaff, AWet al. (2002). Litomosoides sigmodontis cystatin acts as an immunomodulator during experimental filariasis. International Journal for Parasitology 32(2), 171-178.
40. Pokharel, DR et al. (2006). Vaccination with Setaria cervi 175 kDa collagenase induces high level of protection against Brugia malayi infection in jirds. Vaccine 24(37-39), 6208-6215.
41. Ramachandran, S et al. (2004). The larval specific lymphatic filarial ALT-2: induction of protection using protein or DNA vaccination. Microbiology and Immunology 48(12), 945-955.
42. Vedi, S et al. (2008). Vaccination with 73kDa recombinant heavy chain myosin generates high level of protection against Brugia malayi challenge in jird and mastomys models. Vaccine 26(47), 5997-6005.
43. Veerapathran, A et al. (2009). Evaluation ofWuchereria bancrofti GST as a vaccine candidate for lymphatic filariasis. PLoS Neglected Tropical Diseases 3(6): e457.
44. Wang, SH et al. (1997). Evaluation of recombinant chitinase and SXP1 antigens as antimicrofilarial vaccines. American Journal of Tropical Medicine and Hygiene 56(4), 474-481.
45. Weil, GJ et al. (1992). Brugia malayi: antibody responses to larval antigens in infected and immunized jirds. Experimental Parasitology 74(3), 315-323.
46. Williams, SA et al. (2000). The filarial genome project: analysis of the nuclear, mitochondrial and endosymbiont genomes of Brugia malayi. International Journal for Parasitology 30(4), 411-419.
47. Yates, JA & Higashi, GI (1985). Brugia malayi: vaccination of jirds with 60cobalt-attenuated infective stage larvae protects against homologous challenge. American Journal of Tropical Medicine and Hygiene 34(6), 1132-1137.
48. Yates, JA & Higashi, GI (1986). Ultrastructural observations on the fate of Brugia malayi in jirds previously vaccinated with irradiated infective stage larvae. American Journal of Tropical Medicine and Hygiene 35(5), 982-987.
49. Bethony, JM et al. (2008). Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults. Vaccine 26(19), 2408-2417.
50. Ghosh, K et al. (1996). Vaccination with alum-precipitated recombinant Ancylostoma-secreted protein 1 protects mice against challenge infections with infective hookworm (Ancylostoma caninum) larvae. Journal of Infectious Diseases 174(6), 1380-1383.
51. Goud, GN et al. (2004). Cloning, yeast expression, isolation, and vaccine testing of recombinant Ancylostoma-secreted protein (ASP)-1 and ASP-2 from Ancylostoma ceylanicum. Journal of Infectious Diseases 189(5), 919-929.
52. Jariwala, AR et al. (2010). Potency testing for the experimental Na-GST-1 hookworm vaccine. Expert Review of Vaccines 9(10), 1219-1230.
53. Tsuji, N et al. (2001). Intranasal immunization with recombinant Ascaris suum 14-kilodalton antigen coupled with cholera toxin B subunit induces protective immunity to A. suum infection in mice. Infection and Immunity 69(12), 7285-7292.
54. Tsuji, N et al. (2003). Mice intranasally immunized with a recombinant 16-kilodalton antigen from roundworm Ascaris parasites are protected against larval migration of Ascaris suum. Infection and Immunity 71(9), 5314-5323.
55. Tsuji, N et al. (2004). Recombinant Ascaris 16-Kilodalton protein-induced protection against Ascaris suum larval migration after intranasal vaccination in pigs. Journal of Infectious Diseases 190(10), 1812-1820.
56. Xiao, S et al. (2008). The evaluation of recombinant hookworm antigens as vaccines in hamsters (Mesocricetus auratus) challenged with human hookworm, Necator americanus. Experimental Parasitology 118(1), 32-40.
57. Zhan, B et al. (2004). Ac-SAA-1, an immunodominant 16 kDa surface-associated antigen of infective larvae and adults of Ancylostoma caninum. International Journal for Parasitology 34(9), 1037-1045.
58. Zhan, B et al. (2005). Biochemical characterization and vaccine potential of a heme-binding glutathione transferase from the adult hookworm Ancylostoma caninum. Infection and Immunity 73(10), 6903-6911.
59. Zhan, B et al. (2010). Molecular cloning, biochemical characterization, and partial protective immunity of the heme-binding glutathione S-transferases from the human hookworm Necator americanus. Infection and Immunity 78(4), 1552-1563.
60. Bacarese-Hamilton, T et al. (2002). Protein microarrays: from serodiagnosis to whole proteome scale analysis of the immune response against pathogenic microorganisms. Biotechniques Suppl, 24-29.
61. Bennuru, S et al. (2009). Brugia malayi excreted/secreted proteins at the host/parasite interface: stage- and gender-specific proteomic profiling. PLoS Neglected Tropical Diseases 3(4): e410.
62. Brindley, PJ et al. (2009). Helminth genomics: The implications for human health. PLoS Neglected Tropical Diseases 3(10), e538.
63. Coler, RN et al. (2009). Adjuvants for malaria vaccines. Parasite Immunology 31(9), 520-528.
64. Coler, RN et al. (2010). A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One 5(10): e13677.
65. DeMarco, R & Verjovski-Almeida, S (2009). Schistosomes- proteomics studies for potential novel vaccines and drug targets. Drug Discovery Today 14(9-10), 472-478.
66. Doolan, DL (2011). Plasmodium immunomics. International Journal for Parasitology 41(1), 3-20.
67. Foster, J et al. (2005). The Wolbachia genome of Brugia malayi: endosymbiont evolution within a human pathogenic nematode. PLoS Biology 3(4), e121.
68. Ghedin, E et al. (2007). Draft genome of the filarial nematode parasite Brugia malayi. Science 317(5845), 1756-1760.
69. Grieve, RB et al. (1988). Induction of protective immunity in dogs to infection with Dirofilaria immitis using chemically-abbreviated infections. American Journal of Tropical Medicine and Hygiene 39(4), 373-379.
70. Huleatt, JW et al. (2007). Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25(4), 763-775.
71. Huleatt, JW et al. (2008). Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26(2), 201-214.
72. Kwissa, M et al. (2007). The science of adjuvants. Expert Review of Vaccines 6(5), 673-684.
73. Marchand, M et al. (2003). Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. European Journal of Cancer 39(1), 70-77.
74. Pashine, A et al. (2005). Targeting the innate immune response with improved vaccine adjuvants. Nature Medicine 11(4 Suppl), S63-68.
75. Vasilakos, JP et al. (2000). Adjuvant activities of immune response modifier R-848: comparison with CpG ODN. Cellular Immunology 204(1), 64-74.
76. Vernacchio, L et al. (2002). Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers. Vaccine 20(31-32), 3658-3667.
77. Waite, DC et al. (2001). Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 19(28-29), 3957- 3967.